ArticleJournal of cellular biochemistry2015
Reduction of myeloid-derived suppressor cells and lymphoma growth by a natural triterpenoid.
Article in Journal of cellular biochemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 45 citations in OpenAlex.
- Ganoderic Acid A Attenuates Pathological Cardiac Hypertrophy by Attenuating Inflammatory Responses.Current issues in molecular biology · 2026Article
- The Inclusion of Dietary and Medicinal Mushrooms into Translational Oncology: Pros and Cons at the Molecular Level.International journal of molecular sciences · 2026Review
- CanPharmaceuticals (Basel, Switzerland) · 2025Review
- Ganoderic acid a derivative induces apoptosis of cervical cancer cells by inhibiting JNK pathway.Chinese herbal medicines · 2025Article
- Crosstalk between autophagy and apoptosis in initiating antitumor immune responses in human lymphoma cells.Exploration of immunology · 2025Article
- Using a Natural Triterpenoid to Unlock the Antitumor Effects of Autophagy in B-Cell Lymphoma.Biomedicines · 2025Article
- Distributions of Lanostene-Derived Triterpenoids and Glucan Content in the Fruiting Bodies of the AustralianJournal of fungi (Basel, Switzerland) · 2024Article
- Pharmacological modulation of myeloid-derived suppressor cells to dampen inflammation.Frontiers in immunology · 2022Review
- Identification of an Oxidosqualene Cyclase Gene Involved in Steroidal Triterpenoid Biosynthesis inGenes · 2021Article
- Ganoderic acid hinders renal fibrosis via suppressing the TGF-β/Smad and MAPK signaling pathways.Acta pharmacologica Sinica · 2020Article
- Ionic Liquid-Based Ultrasonic-Assisted Extraction Coupled with HPLC and Artificial Neural Network Analysis forMolecules (Basel, Switzerland) · 2020Article
- Screening Immunoactive Compounds ofFrontiers in pharmacology · 2020Article
- Quercetin Synergistically Inhibit EBV-Associated Gastric Carcinoma withMolecules (Basel, Switzerland) · 2019Article
- Ganoderic acid A exerts antitumor activity against MDA-MB-231 human breast cancer cells by inhibiting the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway.Oncology letters · 2018Article
- Ganoderic acid A inhibits proliferation and invasion, and promotes apoptosis in human hepatocellular carcinoma cells.Molecular medicine reports · 2017Article
- Screening and Analysis of the Marker Components in Ganoderma lucidum by HPLC and HPLC-MSMolecules (Basel, Switzerland) · 2017Article
- Ganoderic Acid A Metabolites and Their Metabolic Kinetics.Frontiers in pharmacology · 2017Article
- Anticancer Activity of Ganoderic Acid DM: Current Status and Future Perspective.Journal of clinical & cellular immunology · 2017Article
- Structure Identification and Anti-Cancer Pharmacological Prediction of Triterpenes from Ganoderma lucidum.Molecules (Basel, Switzerland) · 2016Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Lymphoma is a potentially life threatening disease. The goal of this study was to investigate the therapeutic potential of a natural triterpenoid, Ganoderic acid A (GA-A) in controlling lymphoma growth both in vitro and in vivo. Here, we show that GA-A treatment induces caspase-dependent apoptotic cell death characterized by a dose-dependent increase in active caspases 9 and 3, up-regulation of pro-apoptotic BIM and BAX proteins, and a subsequent loss of mitochondrial membrane potential with release of cytochrome c. In addition to GA-A's anti-growth activity, we show that lower doses of GA-A enhance HLA class II-mediated antigen (Ag) presentation and CD4+ T cell recognition of lymphoma cells in vitro. The therapeutic relevance of GA-A treatment was also tested in vivo using the EL4 syngeneic mouse model of metastatic lymphoma. GA-A-treatment significantly prolonged survival of EL4 challenged mice and decreased tumor metastasis to the liver, an outcome accompanied by a marked down-regulation of STAT3 phosphorylation, reduction myeloid-derived suppressor cells (MDSCs), and enhancement of cytotoxic CD8+ T cells in the host. Thus, GA-A not only selectively induces apoptosis in lymphoma cells, but also enhances cell-mediated immune responses by attenuating MDSCs, and elevating Ag presentation and T cell recognition. The demonstrated therapeutic benefit indicates that GA-A is a candidate for future drug design for the treatment of lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.